The award is a recognition for his significant contribution to the development of research in multiple sclerosis within the Catalan Institute of Health.

The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.

The funds will enable the recruitment and retention of young talent, as well as the development of a new epigenetic drug

This strategy protects almost two thirds of patients. It also reduces the waiting time between vaccination and initiation of immune suppressive treatment.

The initiative, coordinated by Dr. Pablo Velasco and Dr. Jose Luis Fuster, aims to bring innovation closer to patients and promote research projects in this disease.

The ability to be able to diagnose and differentiate both diseases as early as possible is fundamental to impact and stop the evolution of the disease before irreversible damage occurs.

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

This initiative has several collaborative projects with the aim of increasing knowledge about rare blood diseases and improving patient care.

The results of the study show for the first time that patients who start treatment less than six months after having the first symptoms of the disease have a slower progression and less disability than when therapy is started more than 16 months later.

The multicenter phase 1 trial has been conducted in patients aged 2 to 21 years with solid tumors unresponsive to standard treatments or in relapse.

Recently, a closing meeting was organised to wrap up the first phase of the study, which aims at grouping sufficient data of patient affected by these pathologies.

This is the most prestigious international award in the multiple sclerosis scientific and social community, given in recognition of life-long work in care, research and teaching in relation to the disease.

The finding opens the door to the development of new therapies that block neurodegeneration, beyond current treatments that focus on the inflammatory process and the control of relapses.

The presentations include the one given by Dr. María Pérez Torres, who received the award for the best oral communication for a project on the use of mesenchymal cells to reduce complications after hematopoietic progenitor transplantation.

Thanks to the donation, the Childhood Cancer and Blood Disorders group at VHIR is doing research to explore the use of liquid biopsy for the prediction of the evolution of patients with this rare disease.

Dr. Lucas Moreno is the first author of the international work that presents a series of considerations for early phase studies with the aim of accelerating the arrival of new therapies to patients with childhood cancer.

Júlia Baguña, Andrea Guala i Roberto Orsenigo han rebut una dels 105 ajuts concedits en el marc del programa INPhINIT i les 40 del programa Junior Leader.

El 20% dels pacients en els quals s’havia trobat alguna predisposició genètica van ser diagnosticats amb algun tipus de tumor i van poder iniciar el tractament de manera precoç.

The funded project is investigating the biological mechanisms of metastasis and hopes to improve the survival of patients with this type of tumor with the development of new therapies.

The call will fund a project on the impact of the Low Emission Zone on the incidence of arrhythmias and another to stop liver disease related to alcohol consumption.

SIOPEN promotes research and the implementation of clinical trials to improve clinical practice in this type of childhood tumor.

RADeep aims to map at the European level the diagnostic methods, demography, survival rate, main clinical features and treatments of rare anaemia disorders patients.

Vall d’Hebron ha celebrat avui la Jornada del Dia Mundial contra el Càncer, una malaltia cada cop més freqüent que patiran al llarg de la vida un de cada dos homes i una de cada tres dones del nostre entorn.

Research has found that a significant number of patients with the Relapsing-Remitting variant have Progression Independent of Relapse Activity episodes.